Equity Field Notes from temporal sources

[DanWebzster]

ALXO is a recent IPO that competes with GILD and TRIL in an area of oncology known as CD47 Blockade.

MRK is collaborating with ALXO in head and neck cancer (HNC) using Keytruda in combo studies.

Because the results of their Ph2b study in second-line HNC were quite encouraging, there are high hopes that their next study in first-line patients will progress toward commercialization.

The 2027 TAM for HNCs is expected to be $4.5B.

Gross proceeds from the 7/20 ALXO IPO were ~$172M and their cash runway could take them through 2023.